21st Austria weekly - Valneva, S&T, Strabag (06/04/2021)
21st Austria weekly - Valneva S&T Strabag 06/04/2021 [pic1]Valneva: an Austrian/French specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need today announced positive data Part A Phase 1/2 clinical trial its inactivated adjuvanted COVID-19 candidate VLA2001. Based this data Company plans to commence a 3 by end April 2021 subject regulatory approval. In study VLA2001-201 three dose levels VLA2001 low medium high based schedule two doses vaccinations weeks apart were evaluated...
Source: boerse-social.com